ID: ALA4467000

Max Phase: Preclinical

Molecular Formula: C17H17N3O2S

Molecular Weight: 327.41

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC(C)c1ccc(Oc2ccnc3sc(C(N)=O)c(N)c23)cc1

Standard InChI:  InChI=1S/C17H17N3O2S/c1-9(2)10-3-5-11(6-4-10)22-12-7-8-20-17-13(12)14(18)15(23-17)16(19)21/h3-9H,18H2,1-2H3,(H2,19,21)

Standard InChI Key:  YUWBWVLAHVEPML-UHFFFAOYSA-N

Associated Targets(non-human)

Alkaline phosphatase tissue-nonspecific 94 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 327.41Molecular Weight (Monoisotopic): 327.1041AlogP: 3.89#Rotatable Bonds: 4
Polar Surface Area: 91.23Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 0.84CX LogP: 3.55CX LogD: 3.55
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.76Np Likeness Score: -1.15

References

1. Saito K, Shinozuka T, Nakao A, Kiho T, Kunikata T, Shiiki T, Nagai Y, Naito S..  (2019)  Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.,  29  (14): [PMID:31101474] [10.1016/j.bmcl.2019.05.014]

Source